Source: International Congress 2014 – ILDs 4
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Sterclova, P. Paluch, K. Heinzelmann, O. Eickelberg, M. Vasakova (Prague, Czech Republic; Munich, Germany). Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases. Eur Respir J 2014; 44: Suppl. 58, 3745

Member's Comments

No comment yet.

Related content which might interest you: Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 Mucus production, lung inflammation and functional decay in IPF Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Parenchymal cell populations involved in the development of fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Epithelial mesenchymal transition in fibroblastic foci of different fibrosing lung diseases: Repair or remodeling? Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis Year: 2013 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Comparison of physiological impairment in ILD patients with and without diagnostic IPF features Source: International Congress 2014 – ILDs 4 Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Distinct gene expression profiles of cultured stromal cells from the patients with idiopathic pulmonary fibrosis and lung adenocarcinoma Source: International Congress 2015 – Translational studies in airway cell biology Year: 2015 Airway centered interstitial fibrosis – An under-recognized type of idiopathic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 IL-17+ cells immunoexpression in systemic sclerosis pulmonary fibrosis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 6 Year: 2014 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Lung 18F-FDG uptake correlates with lung function alteration in patients with IPF Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014